Aspirin and Mortality in Patients With Diabetes Sustaining Acute Coronary Syndrome
Aspirin and Mortality in Patients With Diabetes Sustaining Acute Coronary Syndrome
复制标题
DOI：
10.2337/dc07-1745
复制
发表时间：
2008-02-01
期刊：
影响因子：
16.2
通讯作者：
Hall, Alistair S.
中科院分区：
文献类型：
--
作者：
Cubbon, Richard M.;Gale, Christopher P.;Hall, Alistair S.
目的：我们试图比较有糖尿病和无糖尿病的急性冠脉综合征(ACS)患者二级预防的死亡率降低。研究设计和方法-我们进行了一项队列研究)，涉及来自11个英国的2499名ACS患者。医院。多变量分析比较了在糖尿病患者和非糖尿病患者中，与药物相关的全因死亡风险降低。结果：阿司匹林与糖尿病患者死亡率的显著提高无关(95%可信区间0.501.08)；非糖尿病患者死亡率降低48%(P<；0.001)。糖尿病和阿司匹林使用之间的交互作用具有统计学意义(P=0.037)，这表明糖尿病患者使用阿司匹林降低死亡率的效果较差。结论阿司匹林与糖尿病和不稳定冠状动脉疾病患者的死亡率降低效果不相关，但与其他二级预防药物无关。
OBJECTIVE - We sought to compare mortality reduction associated with secondary prevention in patients with and Without diabetes after acute coronary syndrome (ACS).RESEARCH DESIGN AND METHODS - We conducted a cohort stud), involving 2,499 patients with ACS recruited from 11 UK. hospitals. Multivariable analysis comparing all-cause mortality risk reduction associated with pharmacologic agents in patients -,with and without diabetes,RESULTS - Aspirin was not associated with significant mortality benefit in diabetes sufferers (95% CI 0.50-1.08); nondiabetic patients derived a 48% mortality reduction (P < 0.001). The interaction between diabetes and aspirin use was statistically significant (P = 0.037), indicating that patients with diabetes experience less effective mortality reduction from aspirin use.CONCLUSIONS - Aspirin, but not other secondary prevention agents, is associated with less effective mortality reduction in patients with diabetes and unstable coronary artery disease.